ClinicalTrials.gg
RecruitingNCT06308055Updated Nov 12, 2026

Abiomed Impella RT-DAQ - Observational Study

An observational study in Cardiogenic Shock, sponsored by Abiomed Inc.. Recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Abiomed Inc. (part of Johnson & Johnson) · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Nov 12, 2026Site recruiting status changedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Shock, Cardiogenic with a site in Germany — 13 open to participants now, 13 under way, none of them phase 3. Shock, Cardiogenic · Germany.

Planned enrollment
8th of 14
125 · median 138
Started
2024
with 2 others
Observational
14 of 36
8 open now
Primary completion
2027-06
later than 3 of 12 live
Registered
29th of 36
by date
Lead sponsor
2 of 36
Abiomed Inc.

Among the 36 studies in Shock, Cardiogenic with a site in Germany, this one is the 8th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2024, is one of 14 observational ones, reaches primary completion later than 3 of the 12 other live ones, and was the 29th registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

13 of the 36 studies in Shock, Cardiogenic with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Shock, Cardiogenic with a site in Germany, or all of them as a file.
02

Study summary

Abiomed IMPELLA-RT-DAQ - Impella Real Time Data AcQuisition

Read the detailed description

The objective of this study is to develop algorithms for determining the cardiac output through the synchronous acquisition of hemodynamic data from the pulmonary artery catheter or other pressure sensors and Impella using a network module, which can replace invasive hemodynamic monitoring in the future.

03

Conditions studied

  • Cardiogenic Shock

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients requiring cardiac Impella pump-support and intensive care therapy including cardiac output monitoring, eg. by pulmonary artery catheter at some point of therapy.

Initially, a collection of 250 patient days is aimed for. It is expected that each patient will be monitored by PAC for at least 48 hours, thus approximately 125 patients will be needed to achieve study objectives.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ongoing or planned intensive care management with Impella support
  2. Presence or planned placement of a cardiac output measurement

    1. Preferentially pulmonary catheter (including cardiac output (CO) preferred as continuous measurement)
    2. Other means of discontinuous CO measurement incl. echocardiography, other thermodilution methods

Exclusion criteria

Exclusion Criteria:

  1. Age \< 18 years
  2. Pregnancy
  3. Anticipated support duration \<24 h
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (estimated)
Target follow-up
2 Days
Patient registry
Yes

Interventions

  • OtherData Acquisition

    Develop algorithms for determining the cardiac output through the synchronous acquisition of hemodynamic data from the pulmonary artery catheter or other pressure sensors and Impella using a network module.

06

What researchers measure

Primary outcomes

  1. Collection of hemodynamic parameters (Cardiac Output in l/min)

    Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access.

    Time frame: From Impella insertion unitl Impella support is permanently weaned, on average 2 days

  2. Collection of hemodynamic parameters (Blood Pressure in mmHg, Pulmonary Artery Pressure in mmHg, Central Venous Pressure in mmHg, Pulmonary Capillary Wedge Pressure in mmHg)

    Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access.

    Time frame: From Impella insertion unitl Impella support is permanently weaned, on average 2 days

  3. Collection of hemodynamic parameters (Mixed Venous Saturation in %)

    Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access.

    Time frame: From Impella insertion unitl Impella support is permanently weaned, on average 2 days

  4. Collection of hemodynamic parameters (Pulmonary Vascular Resistance in In dynes/sec/cm-5 )

    Synchronous data acquisition of the Impella system parameters (pressure measurement, motor current, operating data) and the monitoring system (Philipps IntelliVue) using a network module (HighDim) that is connected by either a wired or wireless access.

    Time frame: From Impella insertion unitl Impella support is permanently weaned, on average 2 days

Secondary outcomes

  1. Rate of Patient Survival

    Time frame: Once the Impella support is permanently weaned, on average 2 days

07

Study locations

3 of 4 sites recruiting
  • Uniklinik RWTH Aachen
    Aachen, North Rhine-Westphalia 52074, Germany
    Active, not recruiting

    Not enrolling at this site.

  • UKSH Campus Kiel
    Kiel, Schleswig-Holstein 24105, Germany
    Recruiting
    • Bernd Panholzer, MD · Principal investigator
  • IRCCS Ospedale San Raffaele
    Milan, MI 20132, Italy
    Recruiting
    • Alberto Zangrillo, MD · Principal investigator
    • Luca Baldetti, MD · Sub investigator
  • Universitätsspital Basel
    Basel, Switzerland
    Recruiting
    • Patrick Hunziker, MD · Contact
    • Patrick Hunziker, MD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jun 2027, 32 months after the start.

Of 85 observational studies under Shock, Cardiogenic, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 24. This study's planned 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Mar 13, 2024
StartActual
Oct 4, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • UKSH Campus Kiel · Kiel, GermanyNot yet recruiting→Recruiting
  • IRCCS Ospedale San Raffaele · Milan, ItalyNot yet recruiting→Recruiting
Nov 12, 2026
Contact
Study contact changed: removed A•••@its.jnj.com · •••8860. See the current contact
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • UKSH Campus Kiel · Kiel, GermanyNot yet recruiting→Recruiting
    • IRCCS Ospedale San Raffaele · Milan, ItalyNot yet recruiting→Recruiting
    Contact Study contact changed: removed A•••@its.jnj.com · •••8860. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06308055
Lead sponsor
Abiomed Inc.
Responsible party
Sponsor
First posted
Mar 13, 2024
Start date
Oct 4, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Kirstin Starke
Contact
KStarke@ITS.JNJ.com
+49 241 8860 ext. 0
Alexander Kersten, MD
principal investigator · Uniklinik RWTH Aachen, Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion